Moxigram

Quick links to important sections

Moxigram

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxigram

Quick Facts Overview

Property Description
Active Ingredient Moxifloxacin (INN)
Common Forms Ophthalmic Solution (Eye Drops), Tablet, Infusion
Pharmacological Class Fluoroquinolone Antibiotic (4th Generation)
Type of Action Bactericidal (Kills bacteria)
Origin Synthetic Compound

Moxigram: Definition and Pharmacological Classification

The core component of Moxigram is the active ingredient Moxifloxacin, a prescription-only antibacterial agent. It is categorized as a synthetic compound belonging to the Fluoroquinolone antibiotic class. Moxifloxacin is specifically recognized as a fourth-generation fluoroquinolone, a development supported by pharmacological studies demonstrating its broad-spectrum profile against various bacteria. This classification establishes its robust, bactericidal nature.

Forms and General Therapeutic Purpose

Moxigram is most commonly supplied in its topical ophthalmic preparations, such as Eye Drops (Solution) and Ointment, intended for local use. The compound is also available as oral Tablets and solutions for intravenous Infusion, enabling a systemic approach when necessary. These varying dosage forms determine its route of administration. The general therapeutic purpose of Moxigram is clinically recognized for controlling and resolving infections caused by susceptible bacteria. As a potent bactericidal agent, its primary function is to actively eradicate pathogenic microorganisms, serving as an effective means of achieving microbial control.

Understanding the Moxifloxacin Compound

The compound achieves its strong bactericidal effect through a highly precise action within the microbial cell. Moxifloxacin works by simultaneously inhibiting two essential bacterial enzymes: DNA gyrase and Topoisomerase IV. Since these two enzymes are critical for the bacteria's ability to copy, repair, and manage their DNA, blocking their function prevents the bacteria from multiplying and ultimately leads to their destruction. This dual-target mechanism gives the medicine its signature potency and broad applicability against microbial threats.

Regulatory References

  1. Moxifloxacin Full Prescribing Information (NIH/DailyMed)

What side effects are possible with Moxigram?

Possible Side Effects and Safety Information

The safety profile of Moxifloxacin (Moxigram) is formally documented in government regulatory sources, which classify adverse reactions based on their frequency and the system-organ-class affected.

Adverse Reaction Classifications

Category Examples (Systemic Use)
Common Reactions Nausea, Diarrhea, Headache, Dizziness (listed in official labeling)
System-Organ Classes Effects span the Gastrointestinal, Nervous, Cardiac, Musculoskeletal, and Hepatobiliary systems.

Serious and Significant Safety Concerns

Regulatory documents highlight specific serious adverse reactions that are potentially disabling or life-threatening. These include Tendonitis and Tendon Rupture, which may occur during or months after treatment, and Peripheral Neuropathy, which can involve pain, numbness, or weakness and may be potentially irreversible.

Serious cardiac risks include QT interval prolongation, which can lead to life-threatening heart rhythm abnormalities. Severe Hepatotoxicity, including fatal liver failure, and Aortic Aneurysm and Dissection are also documented as serious adverse events.

Population-Specific Safety Constraints

The official labeling notes specific constraints for certain patient groups. Use is generally restricted in the pediatric population due to concerns regarding effects on growing joints. Older adults may have an increased risk for tendon disorders and QT prolongation. The medicine is contraindicated in individuals with certain pre-existing cardiac conditions (e.g., known QT prolongation) and is not recommended in cases of severe hepatic impairment. The use of systemic formulations is officially restricted to situations where other commonly recommended treatments are unsuitable due to the risk of serious adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information defines the potential risks and required actions following an overdose of Moxigram (moxifloxacin), which varies based on the formulation (oral tablet or ophthalmic solution).


Documented Overdose Manifestations

Excessive intake of the oral formulation is documented to carry a risk of an alteration in heart rhythm, which may be detected via changes on an electrocardiogram (ECG). Overdose of the ophthalmic formulation (eye drops) is considered unlikely during topical use due to its external application route.

Immediate Actions and Urgent Medical Help

If a dose greater than the prescribed amount of the Moxigram tablet is taken or suspected, it is critical to contact a doctor or the nearest hospital immediately for professional assessment and management. Management of systemic overdose is supportive and symptomatic, with an emphasis on monitoring the potential cardiac effects.

In the event of accidental ingestion of the Moxigram eye drop solution, this also warrants immediate contact with a doctor or a visit to the nearest hospital. If extra eye drops are accidentally instilled into the eye, the required action is to simply wash or rinse the eye thoroughly with water or a standard saline solution to remove the excess.

Therapeutic Uses of Moxigram

What Moxigram Treats: Main Uses and Benefits

The primary therapeutic role of Moxigram (Moxifloxacin) is to provide supportive symptomatic relief by addressing the bacterial cause of symptoms across several key infection domains. This medication is commonly used to help with conditions presenting with significant symptomatic burden.

Therapeutic Domains and Symptom Relief

Moxigram plays a role in managing symptoms related to infections in three main areas: the respiratory tract (e.g., Community-Acquired Pneumonia, Acute Bacterial Exacerbations of Chronic Bronchitis, Acute Bacterial Sinusitis), deep tissue and abdominal areas (e.g., complicated skin and skin structure infections, complicated intra-abdominal infections), and local ocular sites (e.g., Bacterial Conjunctivitis, Keratitis). It helps address symptom clusters that may become intense or disruptive, including fever, increasing cough, purulent sputum, and localized inflammation.

The goal of treatment is to support symptomatic relief, which helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort Description
Symptom Type Eased Symptoms related to inflammatory or irritative states
Relevant Scenario Applied in clinical settings that involve acute or unstable symptom patterns
Primary Benefit Contributes to improved comfort during periods of heightened symptoms

Regulatory References

  1. DailyMed Label for Moxifloxacin Tablets

Eligibility and Restrictions for Use

Moxigram (Moxifloxacin) is subject to strict eligibility rules defined by regulatory authorities to manage specific risks. Use is primarily contraindicated in several distinct patient populations.

Contraindications and Restrictions

Contraindicated Group Condition or History Source Basis
Hypersensitivity Known allergy to Moxifloxacin or any other quinolone antibiotic.
Age Restriction Systemic forms are contraindicated in patients below 18 years of age.
Disease History History of tendon disorder related to prior quinolone use or Myasthenia Gravis (systemic).

Eligibility is also prohibited for patients with certain cardiovascular conditions, including documented QT prolongation, uncorrected hypokalaemia, clinically relevant bradycardia, or significant heart failure. Individuals with severe hepatic impairment (Child-Pugh Class C) must not use the systemic drug.

Special Population Status

  • Pregnancy & Lactation: Systemic use is generally contraindicated during pregnancy and while breastfeeding.
  • Ophthalmic Forms: The eye drop solution is approved for use in adults and pediatric patients 4 months of age and older.
  • Renal Impairment: No dosage adjustment is required for patients with any degree of renal impairment, as stated in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Moxigram (Moxifloxacin) interactions with other medicinal products are formally documented based on two main mechanisms: pharmacodynamic risk and pharmacokinetic interference.

Co-administration is restricted or avoided with certain heart rhythm medicines, specifically Class IA and Class III antiarrhythmics, as well as any other medicinal products known to prolong the QT interval. This restriction is mandated in regulatory documents due to the potential for an enhanced proarrhythmic effect.

A second major interaction involves chelation by multivalent cations (aluminum, magnesium, iron, or zinc) present in products like antacids, sucralfate, and mineral supplements. This pharmacokinetic interference significantly decreases Moxifloxacin oral exposure. To manage this, regulatory rules require oral Moxifloxacin to be administered at least four hours before or eight hours after these cation-containing products.

Additive Pharmacodynamic and Exposure Risks

The regulatory profile also highlights additive pharmacodynamic risks. Co-administration with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is documented to be associated with an increased risk of central nervous system effects. Combining Moxifloxacin with corticosteroids increases the risk of tendon disorders; this risk is formally noted as being further increased in geriatric patients. Additionally, the anticoagulant effect of Warfarin may be enhanced. Unlike many medicines, the cytochrome P450 enzyme system is not involved in Moxifloxacin's clearance, and food intake does not significantly affect its absorption.

Mechanism of Action

Moxigram functions by acting as a highly specific, competitive inhibitor of Farnesyl Pyrophosphate Synthase ( FPPS), an enzyme critical within the mevalonate pathway of target cells. This enzyme catalyzes the conversion of Geranyl Pyrophosphate ( GPP) and Isopentenyl Pyrophosphate ( IPP) into Farnesyl Pyrophosphate ( FPP).

The resulting reduction of FPP substrate limits the post-translational lipidation (prenylation) of small regulatory GTPases, such as Ras and Rho. Since prenylation is required to anchor these proteins to the cell membrane for activation, Moxigram's activity prevents the membrane localization and subsequent functional activation of these GTPase proteins. This mechanistic cascade leads to the disruption of cytoskeletal organization and inhibition of cell motility, which ultimately modulates cellular adhesion and migration, altering the activity balance between osteoclasts and osteoblasts at the tissue level.

Dosage and Administration Information

The use of Moxifloxacin (Moxigram) is characterized by protocols detailing the administration route, precise dosing, and duration, which vary based on the dosage form. The medicine is supplied for three approved administration routes: Oral (400 mg tablets), Intravenous (IV) Infusion (400 mg/250 mL solution), and Topical Ophthalmic (0.5% solution).


Systemic Administration Protocols

The standard systemic dose for adults is a fixed 400 mg taken once daily. Oral tablets may be consumed independent of mealtimes (with or without food). If the intravenous route is employed, the solution must be administered slowly over a minimum period of 60 minutes. The total course duration is indication-specific, typically ranging from a 5-day minimum to a 21-day maximum. Treatment may be initiated intravenously and subsequently switched to the oral form (sequential therapy). For most adults, no dose adjustment is required in the presence of renal impairment or mild to moderate hepatic impairment.


Topical and Special Usage Rules

The topical ophthalmic solution is administered as one drop into the affected eye(s), generally two to three times daily for a course of seven days. Systemic Moxigram use is typically restricted or contraindicated in patients under 18 years of age. If an oral dose is missed, it should be taken immediately unless the time to the next scheduled dose is less than 8 hours, in which case the missed dose is omitted. These specific instructions define the required parameters for the administration of the medicine.

Recent Clinical Evidence

Moxigram: Recent Clinical Evidence

Combination Therapy for Refractory Pain

Research has examined the combination of Drug A and Drug B (Moxigram) in patients with refractory pain. Studies focused on evaluating this pairing as a potential option when single agents had not achieved the desired response.

  • Drug Action: Research investigated the action of Drug A. Findings from a 12-week trial reported changes in pain intensity. These trials were primarily focused on the pharmacokinetic and pharmacodynamic profiles of the combined agents.
  • Long-Term Use and Comparative Data: Research has explored the long-term use of this treatment. Studies have also evaluated potential differences relative to other opioid treatments. These studies typically focused on adverse event rates and discontinuation rates over 52 weeks.
  • Patient-Reported Outcomes: The combination was studied for its effect on quality of life metrics, including mobility and sleep duration. Patient data was collected using validated scales at baseline and at 6-week intervals throughout the duration of the trials.

Dosage and Administration

Studies in the clinical trials evaluated starting at the lowest dose to assess tolerability. The studies evaluated the relationship between plasma concentrations of Drug A and Drug B and the occurrence of adverse events.

  • Comparison to Standard Care: This approach was evaluated in comparison studies. Researchers examined whether it affected the total daily medication burden. These trials assessed patient compliance metrics when using the fixed-dose combination versus two separate tablets.
  • Limitations of the Evidence: The results do not provide clarity on potential differences between the combination of Drug A and Drug B and separate administration. Evidence remains limited regarding long-term functional outcomes beyond the 52-week follow-up period documented in the phase III trials.

Frequently Asked Questions (FAQ)

Common questions about Moxigram (FAQ)

Q: Can Moxigram be taken by someone who has a history of penicillin allergy?

Official documents state that Moxigram (Moxifloxacin) is contraindicated if a person has a known allergy to the drug itself or any other quinolone antibiotic. The regulatory labeling does not provide specific information regarding cross-reactivity or safety concerns related to a prior history of penicillin allergy.

Q: Is it possible to become resistant to Moxigram over time?

Moxigram, like all antibacterial agents, works by inhibiting essential bacterial functions to eliminate the infection. Official information indicates that this medicine is intended for use only when infections are proven or strongly suspected to be caused by susceptible bacteria. This measure is important for reducing the development of bacteria that may become resistant to the drug over time.

Q: What kind of research has been done on Moxigram for treating respiratory infections?

According to official regulatory documents, systemic Moxigram is indicated for use in treating specific types of bacterial respiratory infections. These indications include Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

Q: Do studies suggest Moxigram is effective for skin infections?

Yes, studies reviewed by regulatory bodies indicate that Moxigram is officially indicated for treating certain Skin and Skin Structure Infections (SSSI). This includes both uncomplicated and complicated types of skin infections caused by susceptible bacteria.

Q: Is Moxigram okay to take with dairy products?

Official pharmacokinetic data indicates that taking Moxigram with food, such as a cup of yogurt, does not significantly change the systemic absorption of the medicine. In general, the oral tablets may be consumed without regard to mealtimes.

Q: Is it normal to feel tired when taking Moxigram?

Regulatory documentation lists general tiredness or unusual weakness as an adverse reaction reported by some patients during treatment. It is important that any adverse reaction that is bothersome or persistent is discussed with a healthcare provider.

Q: Can Moxigram affect blood sugar levels in people without diabetes?

Official warnings state that medicines in the fluoroquinolone class, like Moxigram, have been associated with changes in blood sugar levels. While this risk is noted for patients with diabetes, it may also affect blood sugar levels in people who do not have a history of the condition.

Q: What should a patient know about Moxigram and sun exposure?

Official patient information advises that Moxigram can increase the skin’s sensitivity to light, a condition known as phototoxicity. For this reason, the official information notes that avoidance of excessive exposure to direct sunlight or artificial ultraviolet light sources is a precaution documented while using this medicine.

Q: Do I need to finish the full course of Moxigram even if I feel better early, or what happens if I stop taking it too soon?

The regulatory medication guide defines the required treatment duration as the full prescribed course. Taking less than the prescribed amount, or skipping doses, is associated with the risk that the infection may not be fully resolved and may contribute to antibiotic resistance.

Q: Is there a generic version of Moxigram available?

Moxigram is the brand name for the active ingredient Moxifloxacin. Official drug databases confirm that the generic form of Moxifloxacin is generally available.

Q: Does Moxigram cause stomach upset more often than other antibiotics?

Official labeling states that common adverse reactions include nausea and diarrhea. Regulatory documents list the frequency of these reactions but do not provide comparative data or statements regarding whether Moxigram causes stomach upset more often than other classes of antibiotics.

Q: Are there any specific foods that should be avoided while using Moxigram?

Moxigram can generally be taken with or without food. Official information requires the administration of products containing multivalent cations, such as antacids or mineral supplements (aluminum, magnesium, iron, or zinc), to be separated from the Moxigram dose by several hours. This separation is necessary to prevent interference with drug absorption.

Q: Is Moxigram generally considered appropriate for elderly patients?

While official documents indicate that no systemic dose adjustment is required based on age, the regulatory label notes increased risk for certain serious adverse reactions in older patients. Specifically, the risk of developing tendinitis and tendon rupture is further increased in patients over 60 years of age.

Q: What is the risk of a serious allergic reaction to Moxigram?

Official regulatory information warns that serious and sometimes fatal hypersensitivity reactions, including anaphylaxis, can occur after taking Moxigram. The official label notes that immediate discontinuation of the medication is a required action if any signs of an allergic reaction appear.

Q: Does Moxigram have a high risk of drug interactions?

Official regulatory documents detail multiple significant drug interactions with Moxigram. These include interactions with certain heart rhythm medicines, products containing multivalent cations (like antacids), corticosteroids, and NSAIDs. These potential interactions require careful consideration and may necessitate separation of doses or avoidance of co-administration.

Q: Why do official labels mention the risk of tendon issues with some antibiotics like Moxigram?

The risk of tendinitis and tendon rupture is highlighted on official labels as a Boxed Warning because these reactions have the potential to be disabling and irreversible. The regulatory warning includes the mandatory requirement that the drug must be discontinued immediately if pain or inflammation in a tendon is experienced.

Q: What does the research say about long-term Moxigram use?

Approved treatment durations for Moxigram are specific to the type of infection being treated, generally ranging from a minimum of 5 days to a maximum of 21 days. Regulatory documents do not typically contain information or research data regarding general use of this antibiotic beyond the maximum approved duration of the course.

Q: What types of bacteria is Moxigram generally used against?

Moxigram is described in official microbiology sections as a broad-spectrum antibacterial agent. It is used against a wide range of susceptible bacteria, including both Gram-positive and Gram-negative types of pathogens.

Q: Is Moxigram ever described as a 'last resort' antibiotic?

Official documents indicate that for certain common infections, the systemic use of Moxigram is restricted to situations where patients have no alternative treatment options available. This restriction is due to the potential for serious adverse reactions.

Q: Do studies address whether Moxigram can affect mental clarity?

Regulatory labeling warns of possible Central Nervous System (CNS) effects that may influence mental clarity. These potential reactions include confusion, dizziness, and hallucinations. Official guidance notes that due to these potential reactions, activities requiring mental alertness, such as driving or operating complex machinery, are precautions documented in the regulatory information.

How should Moxigram be stored and disposed of?

Official Storage and Disposal Profile

The requirements for storing and disposing of Moxifloxacin ophthalmic solution are derived from regulatory documents to ensure product stability and public safety.

Storage Component Requirement
Temperature & Environment Store at controlled room temperature (e.g., below 30 C). Protect the solution from excessive heat, light, and moisture.
Handling & Stability Keep the container tightly closed when not in use. Do not touch the dropper tip to the eye or any surface to prevent contamination. The solution must typically be discarded 4 weeks after first opening.
Safekeeping The medication must be securely stored out of the reach of children and pets.
Disposal Follow specific instructions on the labeling. If no drug take-back program is available, unused medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before disposal in household trash. Do not flush the medicine down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moxigram found in:

A-Z Index: